64 results
P
12,600 participants
I/C
checkpoint inhibitor pneumonitis (CIP), endocrine and skin irAEs, severe-grade irAEs, low-grade irAEs, multiple irAEs, 1 irAE
O
overall survival (OS), objective response rate (ORR)
P
advanced melanoma patients
I/C
immune checkpoint inhibitors (ICIs), ipilimumab, nivolumab, pembrolizumab, chemotherapy drugs (eg, dacarbazine, carboplatin, and paclitaxel)
O
cumulative incidence of any irAEs (regardless of severity), severe irAEs (grades 3-5)
P
TNBC, metastatic TNBC, early TNBC
I/C
ICI, immune checkpoint inhibitors, different ICI agents
O
progression-free survival (PFS), overall survival (OS), pathologic complete response rate (pCR), grade ≥ 3 treatment-related adverse events (trAEs), immune-related adverse events (irAEs), grade ≥ 3 irAEs
P
patients undergoing total gastrectomy for gastric cancer
I/C
J-pouch (JP) reconstruction, standard Roux-en-Y (RY) esophagojejunostomy
O
dumping syndrome, heartburn symptoms
P
cancer patients
I/C
immune checkpoint inhibitors (ICIs), no immune checkpoint inhibitors
O
immune-related adverse events (irAEs)
P
patients with cancer
I/C
neoadjuvant combination immunotherapy, standard of care
O
incidence of immune-related adverse events (irAEs)
P
adults with breast cancer
I/C
immune checkpoint inhibitors (ICIs), other conventional therapies
O
any-grade and grade 3-5 adverse events (AEs) and immune-related AEs (irAEs)
P
patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease
I/C
complete revascularization (CR), infarct-related artery-only revascularization (IRA-OR)
O
cardiovascular (CV) mortality, myocardial infarction (MI), recurrent revascularization
P
cancer patients with preexisting autoimmune diseases (AID)
I/C
immune checkpoint inhibitors (ICI), no ICI treatment
O
incidence of autoimmune flare, irAE, response rate, and ICI discontinuation
P
muscle-invasive bladder carcinoma
I/C
neoadjuvant PD-(L)1 inhibitors, PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, PD-(L)1 inhibitors plus chemotherapy
O
pCR, pPR, Grade≥ 3 irAEs rate, OS, RFS